S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:RNLX

Renalytix (RNLX) Stock Price, News & Analysis

$0.83
-0.08 (-8.78%)
(As of 03/28/2024 ET)
Today's Range
$0.80
$0.93
50-Day Range
$0.26
$1.47
52-Week Range
$0.24
$4.04
Volume
379,921 shs
Average Volume
2.09 million shs
Market Capitalization
$41.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Renalytix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
501.5% Upside
$5.00 Price Target
Short Interest
Healthy
1.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Renalytix in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Computer And Technology Sector

488th out of 588 stocks

Medical Laboratories Industry

18th out of 20 stocks

RNLX stock logo

About Renalytix Stock (NASDAQ:RNLX)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

RNLX Stock Price History

RNLX Stock News Headlines

3 Ridiculously Enticing Stocks to Buy for Under a Buck
The ProTrader Dashboard is simple to use! (trade demo inside)
Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Renalytix AI Anticipates Medicare Coverage Milestone
BTIG Keeps Their Buy Rating on Renalytix AI (RNLX)
Renalytix: Q1 Earnings Insights
Renalytix PLC ADR RNLX
See More Headlines
Receive RNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/29/2024
Next Earnings (Estimated)
6/14/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:RNLX
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+501.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-45,610,000.00
Net Margins
-1,736.47%
Pretax Margin
-1,736.18%

Debt

Sales & Book Value

Annual Sales
$3.40 million
Book Value
$0.15 per share

Miscellaneous

Free Float
40,821,000
Market Cap
$41.54 million
Optionable
Optionable
Beta
3.09
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. James R. McCullough M.B.A. (Age 56)
    Chief Executive Officer
    Comp: $1.04M
  • Mr. Thomas H. McLain CPA (Age 65)
    M.B.A, President
    Comp: $662.7k
  • Mr. Oliver James Sterling III
    Chief Financial Officer
  • Mr. Fergus Fleming (Age 56)
    Chief Technology Officer
  • Dr. Michael J. Donovan M.D. (Age 69)
    Ph.D., Chief Medical Officer
  • Mr. Howard B. Doran Jr. (Age 63)
    Chief Business Officer
  • Mr. Salim Gulamabbas Hamir F.C.A.
    Company Secretary

RNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Renalytix stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNLX shares.
View RNLX analyst ratings
or view top-rated stocks.

What is Renalytix's stock price target for 2024?

2 brokerages have issued 12 month price objectives for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 501.5% from the stock's current price.
View analysts price targets for RNLX
or view top-rated stocks among Wall Street analysts.

How have RNLX shares performed in 2024?

Renalytix's stock was trading at $0.39 at the start of the year. Since then, RNLX stock has increased by 113.2% and is now trading at $0.8313.
View the best growth stocks for 2024 here
.

Are investors shorting Renalytix?

Renalytix saw a increase in short interest in March. As of March 15th, there was short interest totaling 894,600 shares, an increase of 78.7% from the February 29th total of 500,600 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 0.5 days.
View Renalytix's Short Interest
.

When is Renalytix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 14th 2024.
View our RNLX earnings forecast
.

How were Renalytix's earnings last quarter?

Renalytix Plc (NASDAQ:RNLX) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). The business had revenue of $0.71 million for the quarter, compared to analyst estimates of $0.70 million. Renalytix had a negative trailing twelve-month return on equity of 1,008.88% and a negative net margin of 1,736.47%.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).

When did Renalytix IPO?

Renalytix (RNLX) raised $156 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO.

Who are Renalytix's major shareholders?

Renalytix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (1.76%), Pinnacle Associates Ltd. (1.69%), Granahan Investment Management LLC (0.15%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Renalytix?

Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNLX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners